Sarah Longnus

Dr. Sarah Longnus


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2003 in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
Verified
Journal Article
Closed access
PDF file
SLSarah Longnus
Sarah Longnus
RWRichard B. Wambolt
Richard B. Wambolt
HPHannah L. Parsons
Hannah L. Parsons
RBRoger W. Brownsey
Roger W. Brownsey
MAMichael F. Allard
Michael F. Allard
We tested the hypothesis that activation of AMP-activated protein kinase (AMPK) promotes myocardial glycogenolysis by decreasing glycogen synthase (GS) and/or increasing glycogen phosphorylase (GP) activities. Isolated working hearts from halothane-anesthetized male Sprague-Dawley rats perfused in the absence or presence of 0.8 or 1.2 mM 5-aminoimidazole-4-carboxamide 1-β-d-ribofuranoside (AICAR), an adenosine analog and cell-permeable activator of AMPK, were studied. Glycogen degradation was increased by AICAR, while glycogen synthesis was not affected. AICAR increased myocardial 5-aminoimidazole-4-carboxamide 1-β-d-ribofuranotide (ZMP), the active intracellular form of AICAR, but did not alter the activity of GS and GP measured in tissue homogenates or the content of glucose-6-phosphate and adenine nucleotides in freeze-clamped tissue. Importantly, the calculated intracellular concentration of ZMP achieved in this study was similar to the Kmvalue of ZMP for GP determined in homogenates of myocardial tissue. We conclude that the data are consistent with allosteric activation of GP by ZMP being responsible for the glycogenolysis caused by AICAR in the intact rat heart.

1 July 2004 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
JMJulie R. McMullen
Julie R. McMullen
TSTetsuo Shioi
Tetsuo Shioi
LZLi Zhang
Li Zhang
OTOleg Tarnavski
Oleg Tarnavski
MSMegan C. Sherwood
Megan C. Sherwood
SISeigo Izumo
Seigo Izumo
Ribosomal S6 kinases (S6Ks) have been depicted as critical effectors downstream of growth factor pathways, which play an important role in the regulation of protein synthesis by phosphorylating the ribosomal protein, S6. The goal of this study was to determine whether S6Ks regulate heart size, are critical for the induction of cardiac hypertrophy in response to a pathological or physiological stimulus, and whether S6Ks are critical downstream effectors of the insulin-like growth factor 1 (IGF1)-phosphoinositide 3-kinase (PI3K) pathway. For this purpose, we generated and characterized cardiac-specific S6K1 and S6K2 transgenic mice and subjected S6K1−/−, S6K2−/−, and S6K1−/− S6K2−/− mice to a pathological stress (aortic banding) or a physiological stress (exercise training). To determine the genetic relationship between S6Ks and the IGF1-PI3K pathway, S6K transgenic and knockout mice were crossed with cardiac-specific transgenic mice overexpressing the IGF1 receptor (IGF1R) or PI3K mutants. Here we show that overexpression of S6K1 induced a modest degree of hypertrophy, whereas overexpression of S6K2 resulted in no obvious cardiac phenotype. Unexpectedly, deletion of S6K1 and S6K2 had no impact on the development of pathological, physiological, or IGF1R-PI3K-induced cardiac hypertrophy. These studies suggest that S6Ks alone are not essential for the development of cardiac hypertrophy.

15 April 1996 in Circulation
Verified
Journal Article
Closed access
PDF file
SLSarah Longnus
Sarah Longnus
RWRichard B. Wambolt
Richard B. Wambolt
BSBrett O. SchönEkess
Brett O. SchönEkess
GLGary D. Lopaschuk
Gary D. Lopaschuk
MAMichael F. Allard
Michael F. Allard
Background We determined glycogen turnover and the contribution of glycogen as a source of glucose for aerobic myocardial glycolysis and glucose oxidation in parallel series of isolated, working rat hearts subjected to pulse-chase perfusions. Methods and Results Myocardial glycogen of isolated, working rat hearts was radiolabeled, after 30 minutes of substrate-free glycogen depletion, by perfusion for 60 minutes with buffer designed to stimulate resynthesis of glycogen (1.2 mmol/L palmitate, 11 mmol/L [U- 14 C]- or [5- 3 H]-glucose, 0.5 mmol/L lactate, and 100 μU/mL insulin). Rates of glucose oxidation ( 14 CO 2 production) and glycolysis ( 3 H 2 O production) were then measured by perfusing the hearts for 40 minutes with buffer designed to simulate physiological conditions (0.4 mmol/L palmitate, 0.5 mmol/L lactate, 11 mmol/L [5- 3 H]- or [U- 14 C]-glucose, 100 μU/mL insulin) containing radiolabeled glucose different from that used during resynthesis. During the chase perfusion, rates of glycolysis and glucose oxidation from exogenous glucose were significantly greater than those from endogenous glycogen. Nevertheless, glycogen contributed significantly to myocardial energy production (41% of the overall ATP produced from glucose), and a significantly greater fraction of the glucose from glycogen that passed through glycolysis was oxidized (>50%) compared with the fraction oxidized from exogenous glucose (<20%, P <.05). Myocardial glycogen was simultaneously synthesized and degraded (ie, glycogen turnover) during the chase perfusion, despite net glycogenolysis. Furthermore, enrichment of labeled glucose in glycogen at the end of the chase perfusion, when corrected for newly synthesized glycogen, did not differ from that at the end of the labeling period. Conclusions Thus, glycogen contributes significantly to aerobic myocardial glucose use under these experimental conditions, and the glucose derived from glycogen is oxidized preferentially compared with exogenous glucose. Additionally, substantial myocardial glycogen turnover occurs, and the manner in which glycogen is degraded does not fit the ordered hypothesis of “last glucose on, first glucose off.”

1 February 2010 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
MSM. P. Sajan
M. P. Sajan
GBG. Bandyopadhyay
G. Bandyopadhyay
AMA. Miura
A. Miura
MSM. L. Standaert
M. L. Standaert
SNS. Nimal
S. Nimal
RFRobert Farese
Robert Farese
Activators of 5′-AMP-activated protein kinase (AMPK) 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR), metformin, and exercise activate atypical protein kinase C (aPKC) and ERK and stimulate glucose transport in muscle by uncertain mechanisms. Here, in cultured L6 myotubes: AICAR- and metformin-induced activation of AMPK was required for activation of aPKC and ERK; aPKC activation involved and required phosphoinositide-dependent kinase 1 (PDK1) phosphorylation of Thr410-PKC-ζ; aPKC Thr410 phosphorylation and activation also required MEK1-dependent ERK; and glucose transport effects of AICAR and metformin were inhibited by expression of dominant-negative AMPK, kinase-inactive PDK1, MEK1 inhibitors, kinase-inactive PKC-ζ, and RNA interference (RNAi)-mediated knockdown of PKC-ζ. In mice, muscle-specific aPKC (PKC-λ) depletion by conditional gene targeting impaired AICAR-stimulated glucose disposal and stimulatory effects of both AICAR and metformin on 2-deoxyglucose/glucose uptake in muscle in vivo and AICAR stimulation of 2-[3H]deoxyglucose uptake in isolated extensor digitorum longus muscle; however, AMPK activation was unimpaired. In marked contrast to AICAR and metformin, treadmill exercise-induced stimulation of 2-deoxyglucose/glucose uptake was not inhibited in aPKC-knockout mice. Finally, in intact rodents, AICAR and metformin activated aPKC in muscle, but not in liver, despite activating AMPK in both tissues. The findings demonstrate that in muscle AICAR and metformin activate aPKC via sequential activation of AMPK, ERK, and PDK1 and the AMPK/ERK/PDK1/aPKC pathway is required for metformin- and AICAR-stimulated increases in glucose transport. On the other hand, although aPKC is activated by treadmill exercise, this activation is not required for exercise-induced increases in glucose transport, and therefore may be a redundant mechanism.

15 July 1997 in Circulation
Verified
Journal Article
Closed access
MAMichael F. Allard
Michael F. Allard
SLSarah Longnus
Sarah Longnus
RWRichard B. Wambolt
Richard B. Wambolt
SGShaun R. Granleese
Shaun R. Granleese
DEDean R. English
Dean R. English
GLGary D. Lopaschuk
Gary D. Lopaschuk
BackgroundRates of glycolysis from exogenous glucose are accelerated in hypertrophied hearts. In this study, we determined whether alterations in the metabolism of glycogen, an endogenous storage form of glucose, also occur in hypertrophied hearts.Methods and ResultsRates of glycolysis ([3H]H2O production) and oxidation ([14C]CO2production) from exogenous glucose and glycogen were measured in isolated working hearts from control and aortic-banded rats. Hearts in which glycogen was prelabeled with [5-3H]- or [U-14C]glucose were perfused with buffer containing 11 mmol/L [5-3H]- or [U-14C]glucose (different from the isotope used to prelabel glycogen), 0.4 mmol/L palmitate, 0.5 mmol/L lactate, and 100 μU/mL insulin. Rates of glycolysis from exogenous glucose were greater (3471±114 versus 2665±194 nmol glucose·min−1·g dry wt−1,P<.05, n=4 to 6, mean±SEM) and rates of exogenous glucose oxidation (445±36 versus 619±16 nmol glucose·min−1·g dry wt−1,P<.05, n=4 to 6) were lower in hypertrophied hearts than in control hearts. Rates of glycolysis and oxidation from glycogen were not different between hypertrophied and control hearts. A greater proportion of glycogen was oxidized (80% to 100%) than the proportion of exogenous glucose oxidized (13% to 24%) in both groups. Additionally, 10.5±1.4 and 12.3±1.0 μmol/g dry wt of glycogen was synthesized in hypertrophied and control hearts, respectively, indicating that simultaneous synthesis and degradation (ie, glycogen turnover) occurred in both groups.ConclusionsThus, aerobic myocardial glycogen metabolism in the hypertrophied heart is similar to that observed in the normal heart even though exogenous glucose metabolism is altered in the hypertrophied heart.

1 January 2020 in Theranostics
Verified
Journal Article
Open access
VBVanessa Biemmi
Vanessa Biemmi
GMGiuseppina Milano
Giuseppina Milano
ACAlessandra Ciullo
Alessandra Ciullo
ECElisabetta Cervio
Elisabetta Cervio
Jacopo BurrelloJacopo Burrello
Jacopo Burrello
Lucio BarileLucio Barile
Lucio Barile
Background: After myocardial infarction, necrotic cardiomyocytes release damage-associated proteins that stimulate innate immune pathways and macrophage tissue infiltration, which drives inflammation and myocardial remodeling. Circulating inflammatory extracellular vesicles play a crucial role in the acute and chronic phases of ischemia, in terms of inflammatory progression. In this study, we hypothesize that the paracrine effect mediated by these vesicles induces direct cytotoxicity in cardiomyocytes. Thus, we examined whether reducing the generation of inflammatory vesicles within the first few hours after the ischemic event ameliorates cardiac outcome at short and long time points.